Human Brain Neuropharmacology: A Platform for Translational Neuroscience. 2020

Mike Dragunow
Department of Pharmacology and Hugh Green Biobank, Centre for Brain Research, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand. Electronic address: m.dragunow@auckland.ac.nz.

Central nervous system (CNS) drug development has been plagued by a failure to translate effective therapies from the lab to the clinic. There are many potential reasons for this, including poor understanding of brain pharmacokinetic (PK) and pharmacodynamic (PD) factors, preclinical study flaws, clinical trial design issues, the complexity and variability of human brain diseases, as well as species differences. To address some of these problems, we have developed a platform for CNS drug discovery comprising: drug screening of primary adult human brain cells; human brain tissue microarray analysis of drug targets; and high-content phenotypic screening methods. In this opinion, I summarise the theoretical basis and the practical development and use of this platform in CNS drug discovery.

UI MeSH Term Description Entries
D009480 Neuropharmacology The branch of pharmacology dealing especially with the action of drugs upon various parts of the nervous system. Neuropharmacologies
D001927 Brain Diseases Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM. Intracranial Central Nervous System Disorders,Brain Disorders,CNS Disorders, Intracranial,Central Nervous System Disorders, Intracranial,Central Nervous System Intracranial Disorders,Encephalon Diseases,Encephalopathy,Intracranial CNS Disorders,Brain Disease,Brain Disorder,CNS Disorder, Intracranial,Encephalon Disease,Encephalopathies,Intracranial CNS Disorder
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D057170 Translational Research, Biomedical The endeavour to traverse a specific step of the translation process of turning an observation in the laboratory, clinic, or community into an intervention that will improve the health of individuals and the public. (from Nat Rev Drug Discov. 2018 July ; 17(7): 455–456.) Translational Medical Research,Translational Research,Translational Research, Medical,Biomedical Translational Research,Medical Research, Translational,Medical Translational Research,Research, Biomedical Translational,Research, Medical Translational,Research, Translational,Research, Translational Medical

Related Publications

Mike Dragunow
January 1986, Acta psychiatrica Scandinavica. Supplementum,
Mike Dragunow
January 2013, British journal of pharmacology,
Mike Dragunow
January 2018, Frontiers in neuroscience,
Mike Dragunow
July 2004, Science (New York, N.Y.),
Mike Dragunow
January 2022, Neuroscience applied..,
Mike Dragunow
March 2006, Neurorehabilitation and neural repair,
Copied contents to your clipboard!